Adiacent

Adicet Bio is a clinical-stage biotechnology company pioneering the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The company's proprietary platform engineers off-the-shelf gamma delta T cells with chimeric antigen receptors (CARs) to enhance their tumor-killing capabilities and durability. Its lead candidate, ADI-001, is a CD20-targeting CAR-gamma delta T cell therapy currently being evaluated in clinical trials for B-cell malignancies and lupus nephritis. Adicet aims to leverage the unique innate and adaptive immune properties of gamma delta T cells to provide potent, durable, and accessible treatments for patients with significant unmet medical needs.